Key result
Tamoxifen significantly lowers fasting total and LDL cholesterol compared to placebo in postmenopausal breast cancer.
RCT (n=140)
Double-blind
Randomized
Answers are grounded in this paper and cite their sources.
We conducted a 2-year, randomized, double-blind, placebo-controlled toxicity trial of therapy with tamoxifen (10 mg twice a day) in 140 postmenopausal women with a history of breast cancer and histologically negative axillary lymph nodes. These women had been treated with surgery with or without radiotherapy. At a 3-month evaluation, tamoxifen-treated women showed a significant decrease in fasting plasma levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, which persisted at 6- and 12-month evaluations. During the first 12 months, plasma triglyceride levels increased; small but significant decreases in high-density lipoprotein cholesterol (HDL) were observed in tamoxifen-treated women, but ratios of total cholesterol to HDL cholesterol and of LDL to HDL cholesterol changed favorably. While data relating lipid/lipoprotein profiles and cardiovascular disease are limited in women, current evidence suggests that total cholesterol and possibly low-density lipoprotein cholesterol are risk factors. We conclude that during the first 12 months of treatment, tamoxifen exerts a favorable effect on the lipid profile in postmenopausal women with early stage breast cancer.
No takes yet. Share an insight, caveat, or question.
Love et al. (1990) conducted an RCT in Node-negative breast cancer in postmenopausal women (n=140). Tamoxifen vs. Placebo was evaluated on Fasting plasma lipid and lipoprotein levels (total cholesterol, LDL, HDL, triglycerides). Tamoxifen decreased fasting total and LDL cholesterol at 3, 6, and 12 months compared to placebo in 140 postmenopausal women with breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: